ESR1 and breast cancer: To predict the recurrence probability of breast cancer patients using a quantitative method, we constructed a nomogram that integrated both the ER‐related signature and the conventional clinicopathological factors (Figure 6) to predict 3‐ and 5‐year DFS probability.